{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T13:22:56Z","timestamp":1788268976452,"version":"build-2803163510"},"reference-count":54,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>\n                    Recurrence remains a major cause of failure after curative-intent therapy for hepatocellular carcinoma (HCC), including resection, ablation, and liver transplantation. Current surveillance relies on imaging and serum biomarkers, but radiologic relapse may lag behind biological recurrence. This gap has focused attention on circulating tumor DNA (ctDNA) and related cell-free DNA (cfDNA) approaches as candidate tools for minimal residual disease (MRD) assessment and molecular surveillance. In HCC, however, recurrence is biologically heterogeneous. Post-treatment relapse may arise from residual malignant clones, occult intrahepatic spread, or\n                    <jats:italic>de novo<\/jats:italic>\n                    hepatocarcinogenesis in a chronically injured liver. This complexity shapes assay selection, result interpretation, and the need for multimodal risk assessment. Tumor-informed ctDNA assays are best suited to tracking residual clonal disease, whereas methylation-based and composite cfDNA approaches may also capture low-shedding disease and recurrence-prone liver-field biology. Available studies suggest that postoperative ctDNA positivity, persistent serial positivity, rising molecular burden, and selected high-risk methylation signals are associated with recurrence risk after curative-intent therapy. Yet the evidence base is uneven across treatment settings and assay classes, laboratory methods are not yet standardized, and binary detectable-versus-undetectable reporting is rarely sufficient for clinical interpretation. The central translational question is therefore how ctDNA\/cfDNA information should be used in realistic HCC surveillance pathways. Current evidence supports these assays as adjunctive molecular risk signals, not as standalone treatment triggers. This review synthesizes the evidence, compares assay strategies, outlines multimodal implementation barriers including standardization and cost, and proposes a cautious roadmap for ctDNA-guided recurrence surveillance in HCC.\n                  <\/jats:p>","DOI":"10.3389\/fonc.2026.1920559","type":"journal-article","created":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T13:03:38Z","timestamp":1788267818000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Circulating tumor DNA for minimal residual disease and recurrence surveillance in hepatocellular carcinoma: current evidence and a translational roadmap"],"prefix":"10.3389","volume":"16","author":[{"given":"Yang","family":"Gu","sequence":"first","affiliation":[{"name":"Department of Hepatobiliary and Pancreatic Surgery, Ward I, Jingmen Central Hospital, Jingmen Central Hospital Affiliated to Jingchu University of Technology","place":["Jingmen, Hubei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofeng","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary and Pancreatic Surgery, Ward I, Jingmen Central Hospital, Jingmen Central Hospital Affiliated to Jingchu University of Technology","place":["Jingmen, Hubei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxian","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary and Pancreatic Surgery, Ward I, Jingmen Central Hospital, Jingmen Central Hospital Affiliated to Jingchu University of Technology","place":["Jingmen, Hubei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary and Pancreatic Surgery, Ward I, Jingmen Central Hospital, Jingmen Central Hospital Affiliated to Jingchu University of Technology","place":["Jingmen, Hubei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhigang","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary and Pancreatic Surgery, Ward I, Jingmen Central Hospital, Jingmen Central Hospital Affiliated to Jingchu University of Technology","place":["Jingmen, Hubei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1097\/hep.0000000000000466","article-title":"AASLD practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma","volume":"78","author":"Singal","year":"2023","journal-title":"Hepatology"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2011.12.001","article-title":"EASL clinical practice guidelines on the management of hepatocellular carcinoma","volume":"82","year":"2025","journal-title":"J Hepatol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.11.018","article-title":"BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update","volume":"76","author":"Reig","year":"2022","journal-title":"J Hepatol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v29.i8.1243","article-title":"Predictors of early and late hepatocellular carcinoma recurrence","volume":"29","author":"Nevola","year":"2023","journal-title":"World J Gastroenterol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.amjsurg.2023.08.002","article-title":"Early recurrence of hepatocellular carcinoma in patients after ablation and resection: A propensity score analysis","volume":"228","author":"Wu","year":"2024","journal-title":"Am J Surg"},{"key":"B6","doi-asserted-by":"publisher","first-page":"71","DOI":"10.21037\/hbsn-22-579","article-title":"Management of hepatocellular carcinoma recurrence after liver surgery and thermal ablations: State of the art and future perspectives","volume":"13","author":"Herrero","year":"2024","journal-title":"Hepatobiliary Surg Nutr"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.16231","article-title":"Adverse genomic alterations and stemness features are induced by field cancerization in the microenvironment of hepatocellular carcinomas","volume":"8","author":"Castven","year":"2017","journal-title":"Oncotarget"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17142390","article-title":"Enhancing hepatocellular carcinoma surveillance: Comparative evaluation of AFP, AFP-L3, DCP and composite models in a biobank-based case-control study","volume":"17","author":"Demirtas","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-025-17342-5","article-title":"Enhancing recurrence-free survival prediction in hepatocellular carcinoma: A time-updated model incorporating tumor burden and AFP dynamics","volume":"32","author":"Akabane","year":"2025","journal-title":"Ann Surg Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.21037\/hbsn-24-202","article-title":"Risk of early hepatocellular carcinoma recurrence following liver resection: Arbitrary specification or possible target to improve outcome","volume":"13","author":"Kornberg","year":"2024","journal-title":"Hepatobiliary Surg Nutr"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(23)01796-8","article-title":"Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): A randomised, open-label, multicentre, phase 3 trial","volume":"402","author":"Qin","year":"2023","journal-title":"Lancet"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.aohep.2023.101176","article-title":"Liquid biopsy: New opportunities for precision medicine in hepatocellular carcinoma care","volume":"29","author":"Aquino","year":"2024","journal-title":"Ann Hepatol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2024.0541","article-title":"Liquid biopsy in hepatocellular carcinoma: Challenges, advances, and clinical implications","volume":"31","author":"Park","year":"2025","journal-title":"Clin Mol Hepatol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2022.103747","article-title":"Field cancerization profile-based prognosis signatures lead to more robust risk evaluation in hepatocellular carcinoma","volume":"25","author":"Huang","year":"2022","journal-title":"iScience"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-23-3660","article-title":"Minimal residual disease using a plasma-only circulating tumor DNA assay to predict recurrence of metastatic colorectal cancer following curative intent treatment","volume":"30","author":"Parikh","year":"2024","journal-title":"Clin Cancer Res"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03579-w","article-title":"Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer: 5-year outcomes of the randomized DYNAMIC trial","volume":"31","author":"Tie","year":"2025","journal-title":"Nat Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-23-3321","article-title":"Measurement of ctDNA tumor fraction identifies informative negative liquid biopsy results and informs value of tissue confirmation","volume":"30","author":"Rolfo","year":"2024","journal-title":"Clin Cancer Res"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1080\/14737159.2023.2182191","article-title":"Prognostic and survival impact of BCL9 and RPS6KB1 copy number variation detected from circulating free DNA in hepatocellular carcinoma","volume":"23","author":"Youssef","year":"2023","journal-title":"Expert Rev Mol Diagn"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2017.76.8671","article-title":"Circulating tumor DNA analysis in patients with cancer: American Society of Clinical Oncology and College of American Pathologists joint review","volume":"36","author":"Merker","year":"2018","journal-title":"J Clin Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1002\/1878-0261.12729","article-title":"The effect of surgical trauma on circulating free DNA levels in cancer patients-implications for studies of circulating tumor DNA","volume":"14","author":"Henriksen","year":"2020","journal-title":"Mol Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-023-14860-y","article-title":"Circulating tumor DNA in the immediate postoperative setting","volume":"31","author":"Efthymiou","year":"2024","journal-title":"Ann Surg Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/mc.22359","article-title":"Genome-wide identification of differential methylation between primary and recurrent hepatocellular carcinomas","volume":"55","author":"Cui","year":"2016","journal-title":"Mol Carcinog"},{"key":"B23","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s13045-025-01747-6","article-title":"The genomic and epigenomic abnormalities of plasma cfDNA as liquid biopsy biomarkers to detect hepatocellular carcinoma: A multicenter cohort study","volume":"18","author":"Guo","year":"2025","journal-title":"J Hematol Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1097\/xcs.0000000000001792","article-title":"Quantification of DNA methylation for diagnosis and monitoring of hepatocellular carcinoma","volume":"242","author":"Javanshir","year":"2026","journal-title":"J Am Coll Surg"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcmgh.2022.02.008","article-title":"Liquid biopsy using cell-free or circulating tumor DNA in the management of hepatocellular carcinoma","volume":"13","author":"Lyu","year":"2022","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1007\/s11912-025-01681-3","article-title":"Liquid biopsy in hepatocellular carcinoma: ctDNA as a potential biomarker for diagnosis and prognosis","volume":"27","author":"Yang","year":"2025","journal-title":"Curr Oncol Rep"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1200\/po-24-00934","article-title":"Feasibility of personalized and tumor-informed circulating tumor DNA assay for early recurrence detection in patients with hepatocellular carcinoma","volume":"9","author":"Abdelrahim","year":"2025","journal-title":"JCO Precis Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.21037\/jgo-24-791","article-title":"Tumor-informed circulating tumor DNA assay for surveillance post-liver transplantation in patients with hepatocellular and cholangiocarcinoma","volume":"16","author":"Abdelrahim","year":"2025","journal-title":"J Gastrointest Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1002\/ueg2.70078","article-title":"Recurrence of hepatocellular carcinoma after liver transplantation: The blind spot of HCC management","volume":"13","author":"Ningarhari","year":"2025","journal-title":"United Eur Gastroenterol J"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12082277","article-title":"Clonal hematopoiesis in liquid biopsy: From biological noise to valuable clinical implications","volume":"12","author":"Chan","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-18-0143","article-title":"False-positive plasma genotyping due to clonal hematopoiesis","volume":"24","author":"Hu","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2024.0899","article-title":"Exploring methylation signatures for high de novo recurrence risk in hepatocellular carcinoma","volume":"31","author":"Kim","year":"2025","journal-title":"Clin Mol Hepatol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs-1919497\/v1","article-title":"Longitudinal surveillance of three biomarkers to predict recurrence of hepatocellular carcinoma after radical resection","volume":"35","author":"Tong","year":"2023","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmoldx.2023.09.004","article-title":"Recommendations for cell-free DNA assay validations: A joint consensus recommendation of the Association for Molecular Pathology and College of American Pathologists","volume":"25","author":"Lockwood","year":"2023","journal-title":"J Mol Diagn"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3343\/alm.2022.42.2.141","article-title":"Clinical practice guidelines for pre-analytical procedures of plasma epidermal growth factor receptor variant testing","volume":"42","author":"Shin","year":"2022","journal-title":"Ann Lab Med"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1002\/1878-0261.13105","article-title":"Serial circulating tumor DNA to predict early recurrence in patients with hepatocellular carcinoma: A prospective study","volume":"16","author":"Zhu","year":"2022","journal-title":"Mol Oncol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.834992","article-title":"Prognostic value of postoperative circulating tumor DNA in patients with early- and intermediate-stage hepatocellular carcinoma","volume":"12","author":"Ye","year":"2022","journal-title":"Front Oncol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"83","DOI":"10.2139\/ssrn.4744025","article-title":"Circulating tumor DNA methylation markers for the early diagnosis of hepatocellular carcinoma","volume":"25","author":"Lu","year":"2025","journal-title":"Clin Exp Med"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1097\/sla.0000000000006386","article-title":"Tumor mutational burden from circulating tumor DNA predicts recurrence of hepatocellular carcinoma after resection: An emerging biomarker for surveillance","volume":"280","author":"Wehrle","year":"2024","journal-title":"Ann Surg"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/8019652","article-title":"Prognostic value of circulating tumour DNA in Asian patients with hepatocellular carcinoma: A systematic review and meta-analysis","volume":"2022","author":"Liu","year":"2022","journal-title":"Evid Based Complement Alternat Med"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2025.102908","article-title":"Circulating blood biomarkers for minimal residual disease in hepatocellular carcinoma: A systematic review","volume":"135","author":"Galli","year":"2025","journal-title":"Cancer Treat Rev"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1097\/hc9.0000000000000472","article-title":"Landmark analysis of the risk of recurrence after resection or ablation for HCC: A nationwide study","volume":"8","author":"Kraglund","year":"2024","journal-title":"Hepatol Commun"},{"key":"B43","doi-asserted-by":"publisher","first-page":"789","DOI":"10.3348\/kjr.2024.0550","article-title":"Local ablation for hepatocellular carcinoma: 2024 expert consensus-based practical recommendations of the Korean Liver Cancer Association","volume":"18","author":"Han","year":"2024","journal-title":"Gut Liver"},{"key":"B44","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1001\/jamaoncol.2016.5116","article-title":"Validation of a risk estimation of tumor recurrence after transplant (RETREAT) score for hepatocellular carcinoma recurrence after liver transplant","volume":"3","author":"Mehta","year":"2017","journal-title":"JAMA Oncol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.17998\/jlc.2022.09.08","article-title":"Liquid biopsy for early detection and therapeutic monitoring of hepatocellular carcinoma","volume":"22","author":"Choi","year":"2022","journal-title":"J Liver Cancer"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000022242","article-title":"Clinical value of circulating tumor cells for the diagnosis and prognosis of hepatocellular carcinoma (HCC): A systematic review and meta-analysis","volume":"99","author":"Cui","year":"2020","journal-title":"Med (Baltimore)"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1039\/d5ay01320h","article-title":"Detection and indications of circulating tumor cells in hepatocellular carcinoma","volume":"17","author":"Liu","year":"2025","journal-title":"Anal Methods"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1080\/15384047.2021.1898728","article-title":"Current perspectives on exosomes in the diagnosis and treatment of hepatocellular carcinoma (review)","volume":"22","author":"Xue","year":"2021","journal-title":"Cancer Biol Ther"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03642-9","article-title":"ctDNA guiding adjuvant immunotherapy in urothelial carcinoma","volume":"595","author":"Powles","year":"2021","journal-title":"Nature"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(15)00198-9","article-title":"Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): A phase 3, randomised, double-blind, placebo-controlled trial","volume":"16","author":"Bruix","year":"2015","journal-title":"Lancet Oncol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-19-3015","article-title":"Harmonizing cell-free DNA collection and processing practices through evidence-based guidance","volume":"26","author":"Greytak","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2024.1270","article-title":"Budget impact analysis of circulating tumor DNA testing for colon cancer in commercial health and Medicare Advantage plans","volume":"5","author":"Li","year":"2024","journal-title":"JAMA Health Forum"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1177\/17588359241266164","article-title":"Early evaluation of the effectiveness and cost-effectiveness of ctDNA-guided selection for adjuvant chemotherapy in stage II colon cancer","volume":"16","author":"Kramer","year":"2024","journal-title":"Ther Adv Med Oncol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1186\/s12913-023-09360-4","article-title":"Hepatocellular carcinoma surveillance based on the Australian Consensus Guidelines: a health economic modelling study","volume":"23","author":"Nguyen","year":"2023","journal-title":"BMC Health Serv Res"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1920559\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T13:03:39Z","timestamp":1788267819000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1920559\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,1]]},"references-count":54,"alternative-id":["10.3389\/fonc.2026.1920559"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1920559","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,1]]},"article-number":"1920559"}}